Acknowledgement to Referees
- PDF / 273,959 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 106 Downloads / 172 Views
ACKNOWLEDGEMENT TO REFEREES
Acknowledgement to Referees
© Springer Nature Switzerland AG 2020
Dear Reader, Welcome to the final issue of BioDrugs for 2020. I wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the quality of our content. The high quality of the content published in BioDrugs has been reflected in the most recent Impact Factor of 5.313. This places the journal in the first quartile of the Immunology, Oncology, and Pharmacology & Pharmacy categories. Furthermore, BioDrugs has published content in a timely manner, with an average time from submission to acceptance of 89 days. In 2020, over 60 articles have been published. The most popular of these in terms of downloads from SpringerLink have been The Therapeutic Potential of Nanobodies. https://doi.org/10.1007/s40259-019-00392-z In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies. https://doi.org/10.1007/s40259-020-00412-3 The Path Towards a Tailored Clinical Biosimilar Development. https://doi.org/10.1007/s40259-020-00422-1 Cell-Free Protein Synthesis: A Promising Option for Future Drug Development. https://doi.org/10.1007/s40259-02000417-y Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! https:// doi.org/10.1007/s40259-019-00395-w Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. https:// doi.org/10.1007/s40259-020-00419-w The Importance of Countering Biosimilar Disparagement and Misinformation. https: //doi.org/10.1007/s40259 -020-00433 -y Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. https://doi.org/10.1007/s40259-020-00430-1 Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology. https://doi.org/10.1007/s4025 9-020-00407-0 A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). https://doi.org/10.1007/s40259-019-00398-7 This year has presented many challenges and I would like to take this opportunity to thank all who have contributed to ensuring the journal has thrived despite the extraordinary circumstances that the science community, and the world in general, has faced.
Vol.:(0123456789)
702
Acknowledgement to Referees
I would like to start by thanking the authors of the articles published in BioDrugs over the course of 2020. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success. The quality of published articles is also testament to the diligence of the peer reviewers, whose willingness to share their expertise
Data Loading...
